Finance Watch: High Value Of Exits Keep Biopharma VC Deals At Near-Record Levels

Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.

Finance Watch

The second quarter Venture Monitor report from Pitchbook and the National Venture Capital Association noted a record level of venture capital exits totaling $165.2bn for the first half of 2019, including 42 biopharmaceutical initial public offerings plus mergers and acquisitions totaling $13.9bn.

The Pitchbook-NVCA Venture Monitor noted that the exits were driven largely by initial public offerings – particularly biopharma offerings –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business